Biologics and JAK inhibitors

Where this sits

These medicines are usually considered when the first disease-modifying plan, often centered on methotrexate, is not controlling the RA well enough. They are still treatments aimed at controlling the disease itself, not just symptoms.

If you're still deciding on a first plan, start with conventional DMARDs.

What biologics and JAK inhibitors are

Biologic DMARDs are targeted medicines given by injection or infusion. They include TNF inhibitors and several other mechanism families. JAK inhibitors are targeted medicines taken as pills. They block signaling through enzymes called Janus kinases inside cells.

No single mechanism is best for everyone. The choice depends on the individual situation.

What the evidence shows

In people whose RA remained active despite methotrexate or other conventional DMARDs, biologic medicines improved response, function, remission measures, and slowing of joint damage. Tofacitinib also showed benefit in this setting.

Access rules can affect when you receive a treatment. They don't change what the evidence shows about whether the treatment can work.

The JAK safety conversation

An oral JAK pill can look simpler than an injection. Convenience is not the same as equal safety for every patient.

ORAL Surveillance compared tofacitinib with TNF inhibitors in adults age 50 or older with at least one cardiovascular risk factor. Tofacitinib had higher rates of major cardiovascular events and cancers in that study. Current guidelines also ask clinicians to consider cardiovascular, cancer, and clotting risks when deciding whether a JAK inhibitor is a good fit.

The study did not show that every person taking a JAK inhibitor has the same level of risk. It changed the safety conversation, especially for people who already have factors that raise those risks.

What taking part usually involves

• An injection at home, an infusion visit, or a pill, depending on the medicine.
• Screening and monitoring for infection risk, with your rheumatology team reviewing any precautions you may need.
• Labs on a schedule your clinician sets.
• Often continuing methotrexate if you tolerate it.
• For some injectable medicines, refrigeration, travel planning, and insurance steps.
• A clear plan for what “working” looks like, and when to reassess.

Why there isn't one best option

Biologics and JAK inhibitors include several different mechanisms. The evidence supports this next disease-modifying step when conventional DMARDs are not enough, but it does not identify one option that is best for every person. Health history, prior treatment, infection risk, how the treatment fits into daily life, and access can all influence the choice.